2012年4月28日

2012年份額/ 4月27日下午一製藥公司生產仿製藥,包括其專有延長釋放藥物輸送技術是希望近一輪650萬美元的月。以斯拉的創新使用一個獨特的藥物設計許可的阿肯色大學改善藥物釋放藥物的一致性。公司技術適用於通用配方的品牌藥物,這樣他們就可以不用頻繁或更好的病人的依從性。“我們測試了超過20種不同的藥物;其中四個現在在我們的甜蜜點,”首席執行官Michael Geranen告訴觀眾去年10月在阿肯色大學醫學科學BioVentures私人股本圓桌會議。(看他的解釋公司的技術和策略在下麵的YouTube視頻。)“我們的鉛藥物靶點出售超過20億美元的品牌銷售。我們所有的目標都難以匹配的配方。我們想成為第一個,可能是第二或第三,通用的市場。“調用Geranen沒有返回,但視頻中從10月份開始,他說,一個鉛藥物被發現和原定去年11月開始生產。 He also spoke of a pilot study expected to take place in India in January and February, with the goals of a bioequivalence trial this month, applying for Food and Drug Administration approval thereafter and reloading the pipeline with drug No. 2 sometime this summer. Advertisement At that time, the company was also finalizing a strategic partner agreement with a multinational generic drug company, he said. Without knowing which drugs the company plans to replicate, it’s hard to speculate about its market opportunity or chances of success. But the U.S. generics market is in growth mode, expected to continue growing 10 percent annually through at least next year, as there are still a number of popular drugs with patents set to expire in late 2012 and 2013, including Cymbalta , Aciphex , Singulair and Actos . But a 2009 report from Espicom tags alternate drug delivery technologies as a popular route to gaining a competitive edge in the generics industry and identifies at least 13 companies as active competitors in the field. Formed in 2008, Ezra Innovations has so far raised $4.2 million from 33 investors since April 2011, as noted in the filing.